First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study.

Ren Z, Liang T, Gu S, Gou H, Peng C, Pan Y, Song T, Su H, Cao K, Liang H, Ying J, Geng Z, Yu W, Zhao H, Bai Y, Hao C, Mao Y, Li W, Wang L, Li D, Wang W, Li N, Malhotra U, Qin S

Open source

DOI: 10.1007/s12325-026-03578-4
Published: 2026 Sep
Container: Advances in therapy
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1007/s12325-026-03578-4,
  title = {First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study.},
  author = {Ren Z and Liang T and Gu S and Gou H and Peng C and Pan Y and Song T and Su H and Cao K and Liang H and Ying J and Geng Z and Yu W and Zhao H and Bai Y and Hao C and Mao Y and Li W and Wang L and Li D and Wang W and Li N and Malhotra U and Qin S},
  year = {2026},
  journal = {Advances in therapy},
  doi = {10.1007/s12325-026-03578-4},
  url = {https://doi.org/10.1007/s12325-026-03578-4}
}

RIS

TY  - JOUR
TI  - First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study.
AU  - Ren Z
AU  - Liang T
AU  - Gu S
AU  - Gou H
AU  - Peng C
AU  - Pan Y
AU  - Song T
AU  - Su H
AU  - Cao K
AU  - Liang H
AU  - Ying J
AU  - Geng Z
AU  - Yu W
AU  - Zhao H
AU  - Bai Y
AU  - Hao C
AU  - Mao Y
AU  - Li W
AU  - Wang L
AU  - Li D
AU  - Wang W
AU  - Li N
AU  - Malhotra U
AU  - Qin S
PY  - 2026
JO  - Advances in therapy
DO  - 10.1007/s12325-026-03578-4
UR  - https://doi.org/10.1007/s12325-026-03578-4
ER  -

APA

Z, R., T, L., S, G., H, G., C, P., Y, P., T, S., H, S., K, C., H, L., J, Y., Z, G., W, Y., H, Z., Y, B., C, H., Y, M., W, L., L, W., D, L., W, W., N, L., U, M., & S, Q. (2026). First-Line Pembrolizumab Plus Chemotherapy for Advanced Biliary Tract Cancer: China Subgroup Analysis of the Randomized Phase 3 KEYNOTE-966 Study.. Advances in therapy. https://doi.org/10.1007/s12325-026-03578-4

Source records

pubmed · retrieved 2026-09-26T23:35:29.282Z
europe-pmc · retrieved 2026-09-26T23:35:29.295Z